A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
To explore overall response rate of trastuzumab combined with TS-ONE based chemotherapy in first-line HER2-positive advanced gastric cancer.
HER 2 Positive Advanced Gastric Cancer
DRUG: Trastuzumab, TS ONE, Cisplatin
Overall Response Rate (ORR), 24 months
Progression free survival (PFS), 24 months|Overall survival (OS), 24 months|Time to Treatment Failure (TTF), Clinical Benefit Rate (CBR), Duration of Response (DR), Safety, 24 months
To explore overall response rate of trastuzumab combined with TS-ONE based chemotherapy in first-line HER2-positive advanced gastric cancer.